RA Capital Healthcare Fund LP 4
4 · Artiva Biotherapeutics, Inc. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Artiva Biotherapeutics (ARTV) 10% Owner RA Capital Buys 32,876 Shares
What Happened
- RA Capital Management, L.P. (a reported 10% owner) purchased shares of Artiva Biotherapeutics (ARTV). The filing shows 31,000 shares bought on 2026-06-25 at a weighted-average price of $8.88 ($275,280) and 1,876 shares bought on 2026-06-26 at $8.98 ($16,846), for a combined purchase of 32,876 shares costing approximately $292,126. These transactions are coded "P" (purchase), i.e., outright buys — purchases are generally taken as more informative than routine sales.
Key Details
- Transaction dates and prices:
- 2026-06-25: 31,000 shares at $8.88 (weighted avg) — $275,280.
- 2026-06-26: 1,876 shares at $8.98 — $16,846.
- Total shares bought: 32,876; total cash outlay ≈ $292,126.
- Shares owned after the transactions: not specified in the provided filing excerpt.
- Notable footnotes:
- F1 notes the $8.88 price is a weighted average for purchases ranging $8.62–$8.98.
- F2 clarifies RA Capital Management, L.P. is the adviser to several funds/accounts and that the adviser and related parties disclaim beneficial ownership except to the extent of pecuniary interest.
- Other footnotes (F3–F7) indicate holdings may be held directly by specific funds/accounts.
- The filing remarks that Laura Stoppel, a Principal of the Adviser, serves on Artiva’s board.
- Filing timeliness: Form 4 filed 2026-06-29 reporting the 6/25–6/26 trades; no late-filing indication in the provided excerpt.
Context
- RA Capital is an institutional investment manager (a 10% owner) rather than an individual executive; the adviser structure and disclaimers in the filing mean reported trades reflect the adviser or its funds/accounts, not necessarily personal trades by named individuals.
- These were purchases (not option exercises, gifts, or awards), which some investors view as a mild bullish signal because an institutional holder increased its position.
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Purchase
Common Stock
[F1][F2][F3]2026-06-25$8.88/sh+31,000$275,280→ 16,794,043 total(indirect: See footnotes) - Purchase
Common Stock
[F4][F2][F3]2026-06-26$8.98/sh+1,876$16,846→ 16,795,919 total(indirect: See footnotes)
Holdings
- 264,571(indirect: See footnotes)
Common Stock
[F2][F5] - 826,832(indirect: See footnotes)
Common Stock
[F2][F6] - 68,320(indirect: See footnotes)
Common Stock
[F2][F7]
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.62 to $8.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]Held directly by the Nexus Fund.
- [F6]Held directly by Nexus Fund III.
- [F7]Held directly by the Account.